|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-3
|
|
pubmed:abstractText |
Systematic structure-activity relationship (SAR) studies of a screening lead led to the discovery of a series of thiazolidinediones (TZDs) as potent GPR40 agonists. Among them, compound C demonstrated an acute mechanism-based glucose-lowering in an intraperitoneal glucose tolerance test (IPGTT) in lean mice, while no effects were observed in GPR40 knock-out mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:AkiyamaTaro ETE,
pubmed-author:BergerJoelJ,
pubmed-author:ChangEricE,
pubmed-author:ClineEricE,
pubmed-author:EiermannGeorge JGJ,
pubmed-author:EinsteinMonicaM,
pubmed-author:FengYueY,
pubmed-author:HowardAndrew DAD,
pubmed-author:KhaHH,
pubmed-author:KumarSanjeevS,
pubmed-author:LinSongnianS,
pubmed-author:MeinkePeterP,
pubmed-author:MillsSander GSG,
pubmed-author:MosleyRalphR,
pubmed-author:PetrovAleksandrA,
pubmed-author:SalituroGinoG,
pubmed-author:TanCarina PCP,
pubmed-author:TangChengC,
pubmed-author:ThornberryNancyN,
pubmed-author:YangLihuL,
pubmed-author:ZhouChangyouC,
pubmed-author:ZhouYun-PingYP
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1298-301
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.
|
|
pubmed:affiliation |
Merck Research Laboratories, Rahway, NJ 07065, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
